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Background: Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant
immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate
tolerance, it may induce several adverse effects, such as fibro-interstitial pneumonitis due to the acquisition of
activated myofibroblasts. The exact molecular mechanism associated with epithelial to mesenchymal transition
(EMT) may be crucial also in the liver context. This work examines the role and the molecular mediators of EMT in
hepatic stellate cell (HSC) and human liver cancer cells (HepG2) and the potential role of EVE to maintain the
epithelial phenotype rather than to act as a potential initiators of EMT.
Methods: Real time-PCR and western blot have been used to assess the capability of EVE at low-therapeutic (10 nM)
and high (100 nM) dose to induce an in vitro EMT in HSC and HepG2.
Results: Biomolecular experiments demonstrated that low concentration of EVE (10 nM) did not modify the gene
expression of alpha-smooth muscle actin (α-SMA), Vimentin (VIM), Fibronectin (FN) in both HSC and HepG2 cells,
whereas EVE at 100 nM induced a significant over-expression of all the three above-mentioned genes and an
increment of α-SMA and FN protein levels. Additionally, 100 nM of EVE induced a significant phosphorylation of AKT
and an up-regulation of TGF-β expression in HSC and HepG2 cells.
Discussion: Our data, although obtained in an in vitro model, revealed, for the first time, that high concentration of
EVE may induce EMT in liver cells confirming previous published evidences obtained in renal cells. Additionally, they
suggested that mTOR-I should be administered at the lowest dose able to maximize their important and specific
therapeutic properties minimizing or avoiding fibrosis-related adverse effects.
Conclusions: In summary, if confirmed by additional studies, our results could be useful for researchers to standardize
new therapeutic immunosuppressive and anticancer drugs protocols.Background
Standard immunosuppressive strategies after liver trans-
plantation are based on steroids in combination with
mycophenolic acid or calcineurin inhibitors (CNI); how-
ever their use might be associate with relevant side effects,
most of all chronic renal failure, with an incidence of up
to 20 % [1]. The mTOR inhibitor and immunosuppressant
Everolimus (EVE), in contrast with CNI, is associated with
a low nephrotoxicity [2]. EVE belongs to the rapamycin* Correspondence: amedeo.carraro@ospedaleuniverona.it
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inhibitor of proliferative signal. The main mechanism of
action of this drug is the inhibition of mTORC1 complex,
a regulatory protein kinase involved in lymphocyte prolif-
eration and other developmental processes [3, 4]. EVE has
gained wide interest also in other fields, for example, for
the treatment of cancer, switching to less invasive pheno-
type of tumoral cells and inhibiting angiogenesis [5, 6].
Then, due to this activity it has been proposed in de novo
and maintenance liver transplant immunosuppressive pro-
tocols to prevent or treat hepatocarcinoma (HCC) recur-
rence, with survival benefits [7, 8]. From the cellular point
of view, interestingly, mTOR signaling is also involved in
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I in attenuating fibrogenic pathways has been already ex-
amined in experimental models, showing a reduced accu-
mulation of extracellular matrix (ECM)-producing cells
and ECM components [10]. Then, in consideration of the
role played by mTOR-I against proliferation and fibrogen-
esis, we can suppose that it could alleviate liver fibrosis also
in the transplanted graft. Liver fibrosis, which is evident in
75 % of biopsies performed in long-term liver transplant
(LTx) survivors, may be promoted by the recurrence of na-
tive disease (HCV), hepatotoxicity, de novo disease, non-
alcoholic steatohepatitis, chronic rejection and vascular or
biliary complications [11]. However, despite evident clinical
and experimental advantages of this drug category,
mTOR-I may induce the development of several systemic
side effects including hematological disorders (anemia,
leukopenia and thrombocytopenia), dismetabolism (hyper-
lipidemia, post-transplant diabetes), lymphedema, stoma-
titis and fertility/gonadic toxicity [12–14]. Fibrosis related
pulmonary adverse effects (e.g., lymphocytic interstitial
pneumonitis, bronchiolitis obliterans with organizing
pneumonia and focal pulmonary fibrosis) have been also
showed in the last years by several reports in onco-
logical and renal transplant patients treated with
mTOR-I [15–18]. Our in vitro experimental study has
already evaluated novel cellular aspects of the potential
pro-fibrotic activity of EVE in kidney, showing, for the
first time, that epithelial to mesenchymal transition
(EMT) in renal tubular cells may be activated by high
doses of EVE [19]. It is well known that EMT, a phenotypic
conversion of epithelium to a fibroblastic or myofibroblas-
tic phenotype, may have a pivotal role to induce fibrogen-
esis also in the liver microenviroment [20]. In this context,
rearranged ECM by migratory processes induced by EMT
appears to be of particular importance also in the mechan-
ism of HCC invasion. In fact, a key event in the develop-
ment and progression of cancer is the potential of tumor
cells to migrate and invade into surrounding tissues. AsTable 1 Primers sequence list
Human Forward
α-SMA GAAGAAGAGGACAGCACTG
FN GTGTGTTGGGAATGGTCGTG
VIM AAAACACCCTGCAATCTTTCA
TGF-β CGTGGAGCTGTACCAGAAAT
GAPDH ACACCCACTCCTCCACCTTT
Rat Forward
α-SMA GAAGAAGAGGACAGCACTG
FN CCAGGCACTGACTACAAGA
VIM TGACCGCTTCGCCAACTA
TGF-β ATACGCCTGAGTGGCTGTCT
GAPDH TGAGGACCAGGTTGTCTCregards, involvement of PI3K/Akt/mTOR pathway in the
interactions between HCC cells and non-parenchymal
cells, such as mesenchymal stem cell (MSC), are critical is-
sues for disease progression [21]. Therefore, the aim of our
study has been to analyze whether EVE at low-therapeutic
[10 nM (corresponding to 3-8 ng/mL serum level)] and
high (100 nM) doses might be able to induce in vitro EMT
in human hepatoblastoma cells (HepG2) and to activate
hepatic stellate cells (HSC). This work prompted us to
assess the use of EVE in order to optimize its role in a
tailored immunosuppressive regimen.
Methods
Cell culture and treatments
HepG2 (human liver cancer cells) were purchased from
ATCC and maintained in Dulbecco’s modified Eagle
medium (DMEM) (Invitrogen, Carlsbad, CA, USA). The
medium was supplemented with 10 % fetal bovine serum
(FBS) and 1 % antibiotic penicillin/streptomycin. Cells
were maintained at 37 °C, 5 % CO2 humidified incubator.
Hepatic stellate cells (HSC) were isolated from normal
male Winstar rats. All animals were purchased from
Charles River Laboratories and were housed in the Animal
research Facility of Biological-Chemistry Department. They
were maintained under a 12-h light–dark cycle and given
rat chow and water ad libitum. The animal investigation
was in accordance with the National Institute of Health
guidelines for the care of Laboratory animals and was
approved by the local committee for supervision of animal
experiments at the University Hospital of Padova, Italy.
This is over and above adherence to general guidelines.
HSCs were isolated from normal livers according to a
modified Zhang method [22]; livers were perfused with a
calcium-free buffer solution to wash out the blood, sub-
sequently with a wash solution (calcium-free solution
with CaCl2 0.294 g/L, MgSO4 0.097 g/L) and finally
incubated in a digestion buffer (collagenase 0.6 g/L in
Gey’s Balanced Salt Solution with Ca2+and Mg2+, pH 7.5)Reverse
TCCCATTCCCACCATCAC
GACGCTTGTGGAATGTGTCG
GA CACTTTGCGTTCAAGGTCAAGAC
GATAACCACTCTGGCGAGTC
TCCACCACCCTGTTGCTGTA
Reverse
TCCCATTCCCACCATCAC
CATGATACCAGCAAGGACTT
CGCAACTCCCTCATCTCCT
TGGGACTGATCCCATTGATT
TCCACCACCCTGTTGCTGTA
Fig. 1 Relative α-SMA, VIM and FN gene expression in HSC treated with EVE. Histograms represent relative gene expression of a) α-SMA, b) VIM
and c) FN evaluated by real-time PCR in HSC cells treated or untreated with EVE (10 or 100nM) for 6 or 24 h. Results were normalized to GAPDH
expression. Mean ± S.D. of two separate experiments (error bars) performed in triplicate. *p < 0.05; **p < 0.001 vs untreated cells
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Fig. 2 α-SMA and FN protein expression in HSC treated with EVE.
Western blot analysis was performed to evaluate a) α−SMA and b) FN
expression in HSC cells treated or untreated with EVE (10 or 100 nM)
for 24 h. GAPDH was included as loading control. Representative blot
of three independent experiments
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The organs were cut into small pieces and subjected to
homogenization to produce a single cell-suspension, which
was centrifuged at 1450 × g for 18 min in 12 % (wt/vol)
Nycodenz gradient to obtain a pure HSC fraction. Both the
number and viability of HSCs were determined using the
trypan blue dye exclusion test.
Collected HSCs were washed with Hank’s balanced salt
solution and resuspended at a concentration of 1 × 105
cells/ml, in DMEM (supplemented with 20 % FBS and 1×
antibiotic solution) and cultured on collagen type I coated
well plates (10 μg/ml) in a 5 % CO2-humidified atmos-
phere. Serum-starved cells were subsequently detached for
experiments using trypsin/EDTA solution.
All cell experiments were performed between passages
3 and 4.
Everolimus was kindly provided by Novartis (Basel,
Switzerland) and dissolved in DMSO according to the
manufacturer’s instructions.
HepG2 and HSC cells were plated in complete growth
medium and then starved for 24 h in serum free medium.
Cells were cultured for additional 1, 6 or 24 h with 10 or
100 nM EVE and then assayed for gene and protein ex-
pression. To evaluate the contribution of AKT-activation
cells were pretreated (1 h before) with LY294002 (25 μM).
Gene expression analysis
Total RNA was extracted from the cell monolayer using
the GenElute Mammalian Total RNA Miniprep kit
(Sigma-Aldrich) including DNase treatment (DNase70;
Sigma). Yield and purity were assessed using Nanodrop
(EuroClone) and Agilent 2100 Bioanalyzer, respectively.
Total RNA from each sample was reverse-transcribed
into cDNA using SuperScript II reverse transcriptase
(Invitrogen). Real-time PCR were performed on an
ABI-Prism 7500 using Power SYBR Green Master Mix
2 (Applied Biosystems). A quantitative analysis was per-
formed to evaluate the expression of α-smooth muscle
actin (α-SMA), vimentin (VIM), fibronectin (FN) and
TGFβ normalized to GAPDH. The comparative Ct
method (ΔΔCt) was used to quantify gene expression,
and the relative quantification was calculated as 2-ΔΔCt.
Melting curve analysis was performed to check for any
presence of non-specific amplification products. The
forward and reverse primer sequences are reported in
Table 1 [23].
Western blot
The cells were treated in lysis buffer (50 mMTris-HCl,
pH 5.0, 150 mMNaCl,0.5 % Triton X-100) with Complete
protease inhibitor mixture (Roche Applied Science) and
phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich)
and quantified using the Bio-Rad protein assay. Equal
amounts of proteins were treated in reducing samplebuffer and denatured for 10 min at 100 °C. Protein sam-
ples were then resolved in 10 % SDS-PAGE and electro
transferred to nitrocellulose membranes. Nonspecific
binding was blocked for 2 h at room temperature with
nonfat milk (5 %) in TBST buffer (50mMTris-HCl,
pH 7.4, 150 mM NaCl, 0.1Tween 20). Membranes were
exposed to primary antibody overnight at4 °C and incu-
bated with a secondary peroxidase-conjugated antibody for
1 h at room temperature. The primary antibodies were sc-
9068 for FN, sc-130619 for alpha-SMA, sc-25778 for
GAPDH, sc-7985-R for pAKT (SantaCruz Biotechnology)
and GTX121937 for AKT (GeneTex). The signal was de-
tected with the Super Signals West Pico Chemiluminescent
substrate solution (Pierce) according to the manufacturer’s
instructions. Bands of three independent experiments were
analyzed by the Image J software (National Institutes of
Health) to obtain mean values.
Results
High doses of EVE activate HSC
To characterize the effect EVE on activation of hepatic
stellate cells, we treated primary cultured HSC cells with
different doses of EVE. HSC were analyzed at low pas-
sages (3 or 4) to limit the spontaneous activation. The
treatment with the therapeutic concentration 10nM did
not modify the gene expression of α-SMA, VIM and FN
both after one, six and 24 h. Differentially, the treatment
with 100 nM EVE significantly induced a 1.49 and 1.91
fold increase in α-SMA expression respectively after 6
and 24 h. Moreover the treatment for 24 h with 100 nM
EVE induced a 2.82 and 1.83 fold increase respectively in
Fig. 3 Relative α-SMA, VIM and FN gene expression in HepG2 treated with EVE. Histograms represent relative gene expression of a) α-SMA, b) VIM and
c) FN evaluated by real-time PCR in HepG2 cells treated or untreated with EVE (10 or 100 nM) for 6 or 24 h. Results were normalized to GAPDH
expression. Mean ± S.D. of two separate experiments (error bars) performed in triplicate. *p < 0.05; **p < 0.001 vs untreated cells
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Fig. 4 α-SMA and FN protein expression in HepG2 treated with
EVE. Western blot analysis was performed to evaluate a) α-SMA
and b) FN expression in HepG2 cells treated or untreated with EVE
(10 or 100 nM) for 24 h. GAPDH was included as loading control.
Representative blot of three independent experiments
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100 nM EVE induced also a significant increase in α-SMA
and FN protein levels (Fig. 2).
High doses of EVE activate the EMT program in
hepatocarcinoma cells
Since also other liver components could be affected by
these properties of EVE at high dose, and since the estab-
lishment of a fibrotic condition is a prerequisite in liver
cancer development we evaluated the effect of different
EVE doses in HepG2 cells. The concentration 10 nM Eve
did not induce alterations in α-SMA, VIM and FN gene
expression. On the other hand 100 nM EVE induced aFig. 5 Relative TGF-β gene expression in HSC and HepG2 cells treated with E
real-time PCR in a) HSC and b) HepG2 cells treated or untreated with EVE (10
Mean ± S.D. of two separate experiments (error bars) performed in triplicate. *significant up-regulation of all the three mesenchymal
markers already after six hours (Fig. 3). Protein expression
analysis confirmed an over-expression of α-SMA and FN
induced by 100 nM EVE (Fig. 4).
TGF-β regulation
TGF-β, which is one of the most important factors
involved in EMT and fibrosis, has also been showed to
be potentially regulated by EVE in a dose-dependent
manner. Our results demonstrated that 10 nM EVE did
not influence TGF-β expression, while 100 nM EVE up-
regulated TGF-β expression already after six hours both
in HSC and HepG2 cells (Fig. 5).
AKT activation induced by EVE
Since several studies suggested that mTORC1 inhibition
by EVE may induce AKT activation leading to the at-
tenuation of its therapeutic effects [24] and since AKT is
an important signaling pathway involved in EMT we
evaluated the effect of EVE in AKT activation.
Western blot analysis of pAKT/AKT revealed that a high
dosage of EVE (100 nM) induced a phosphorylation of
AKT both in HSC and HepG2 cells whereas therapeutic
concentrations (10 nM) had no effects (Fig. 6). Moreover
to prove that the activation of EMT program in HepG2
cells is mediated by the AKT pathway we inhibited its acti-
vation whit LY 294002 (Fig. 7). Gene expression analysis
confirmed that the up-regulation of α-SMA, FN and TGF-
β induced by 100 nM EVE is prevented by the inhibition
of AKT (Fig. 8).
Discussion
Since their introduction in liver transplant therapy, mTOR
inhibitors have been considered promising immunosup-
pressant due to their relatively low nephrotoxicity [2, 25];
the use of EVE is gaining acceptance as maintenance in de
novo liver transplant, in cases of renal dysfunction as a
CNI-sparing regimen and in patients transplanted forVE. Histograms represent relative gene expression of TGF-β evaluated by
or 100 nM) for 6 or 24 h. Results were normalized to GAPDH expression.
p < 0.05; **p < 0.001 vs untreated cells
Fig. 6 AKT phosphorylation in HSC and HepG2 cells treated with EVE.
Western blot analysis was performed to evaluate pAKT and AKT
expression in a) HSC and b) HepG2 cells treated or untreated with EVE
(10 or 100 nM) for 1 h. Representative blot of three independent
experiments
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is the inhibition of cell signaling through the PI3K/Akt/
mTOR pathway [27, 28]. The PI3K/AKT/mTOR signaling
pathway represents a promising target due to its central
role in regulating different cellular activities, including
growth, survival, movement, differentiation and metabol-
ism [29]. Since the main mechanism of action of EVE is
the inhibition of mTORC1 complex, its efficacy might be
due to a feedback activation of upstream PI3K signaling,
leading to AKT hyperactivation [30]. AKT feedback is
thought to be mediated by the inhibition of p70S6 kinase
activity and different mechanisms of its activation have
been proposed [31]. An increase in the phosphorylation of
receptor tyrosine kinases, i.e. EGFR, HER2, HER3 among
others, following treatment with mTOR-I has been dem-
onstrated and may represent an IRS-1-(insulin receptor
substrate 1) independent way of increased AKT signaling.
As regards, Rosich et al reported that the activity of EVE
is limited by AKT re-phosphorylation and suggested that
targeting the PI3K/AKT/mTOR pathway at multiple levels
is likely to be a more effective strategy for the treatment of
mantle cell lymphoma [32]. Thus, despite the known anti-
fibrotic EVE activity, an aberrant signaling with a negative
feedback loop might result in the AKTactivation following
mTOR inhibition; this might be translated into the activa-
tion of cellular processes such as EMT. In fact, as we pre-
viously showed, high concentrations of EVE could induce
renal fibrosis by activating tubular EMT [19]. Therefore,
to evaluate whether EVE treatment was able to interfere
with the liver extracellular microenvironment by inducing
EMT in rat stellate cell (HSC) and human liver cancer cellFig. 7 Inhibition of AKT phosphorylation in HepG2 cells. Western
blot analysis was performed to evaluate pAKT and AKT expression in
HepG2 cells treated or untreated with EVE (10 or 100 nM) for 1 h
and pretreated (1 h before) with 25 μM LY294002lines (HepG2), we measured, by RT-PCR, changes in
expression level of genes encoding for well known EMT
markers (α-SMA, Fibronectin and Vimentin) after both
low-therapeutic (10 nM) and high (100 nM) doses; low
dose has been considered therapeutic as it corresponds to
the usual serum range (3-8 ng/mL) in the liver transplant
setting. Our results demonstrated that the treatment with
the therapeutic concentration 10 nM did not modify the
gene expression of α-SMA, VIM and FN both after six
and 24 h. These data confirm that EVE remains a poten-
tial inhibitor of liver fibrosis at therapeutic concentration,
inhibiting collagen production by activated stellate cells,
as well as cell contraction. Therefore, though therapeutic
dose might attenuate the activation of primary stellate
cells to their activated form, the treatment with 100 nM
EVE (which is higher than the recommended through
level in the liver transplant) significantly induced an
increase in α-SMA, VIM and FN expression. Similarly, as
regards HepG2 cell line, the therapeutic dose (10 nM
EVE) did not induce alterations in α-SMA, VIM and FN
gene expression. On the other hand 100 nM EVE induced
a significant up-regulation of all the three mesenchymal
markers already after six hours (Fig. 3).
These data suggest that progression of liver fibrosis rep-
resents a complex process that involves several patho-
logical events (HSC activation, inflammation etc); on this
basis the inhibition of multiple pathological processes
using a single drug might be uneffective. Then, though
our results are in line with several published papers
reporting potential anti-fibrotic liver properties of both
mTOR-I [9], however different unknown mechanisms
could influence pAKT/AKT signal. Western blot analysis
of pAKT/AKT confirmed that a high dosage of EVE
(100 nM) induces the phosphorylation of AKT both
in HSC and HepG2 cells causing EMT.
Moreover, TGF-β expression is up-regulated by high
dose of EVE (100 nM EVE) after six hours both in HSC
and HepG2 (Fig. 6). Since EVE concentration (e.g, 100
nM) able to induce EMT is higher compared to that
normally used in standard immunosuppressive regimens,
our data might not imply any clinical consequence.
Despite this consideration, in our opinion, our results
highlight a relevant aspect of this drug. Interestingly, al-
though EMT-related effects were reached in our model
only with very high concentration of this drug (beyond the
recommended clinical serum level) we cannot exclude that
other different stimuli or patients with a genetic predispos-
ition could present this condition after exposure to lower or
therapeutic dose of EVE. This assumption is in line with a
recent work published by Xu et al describing a pro-fibrotic
effect of mTOR inhibitors in lung epithelial cells [33].
Altogether, our data, although obtained by an in vitro
model, reveal new biological/cellular aspects of the liver
and systemic pro-fibrotic machinery induced by EVE
Fig. 8 (See legend on next page.)
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Fig. 8 Regulation of α-SMA, FN and TGF-β gene expression in HepG2 treated with EVE by AKT activation. Histograms represent relative gene expression
of a) α-SMA, b) FN and c) TGF-β evaluated by real-time PCR in HepG2 cells treated or untreated with EVE (10 or 100nM) for 6 in presence or not of
the inhibitor LY294002. Results were normalized to GAPDH expression. Mean ± S.D. of two separate experiments (error bars) performed in triplicate.
**p < 0.001 vs untreated cells
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be useful for researchers to develop new therapeutic strat-
egies that may prevent/minimize the systemic fibrotic ad-
verse effects induced by high doses EVE therapy. A
negative feedback loop resulting in the activation of AKT
following mTOR inhibition might also represent a poten-
tially unfavorable event resulting from cancer treatment
with mTOR inhibitors. As regards, the phosphorylation of
AKT pathway at S473 is detected in up to 71 % of HCC
samples, and associated with invasion, metastasis, and
vascularization of HCC as showed by Chen e al [34]. On
the other hand, the EMT program sustained by AKT
feedback-activation may interfere with malignant cell/
microenvironment interactions, thanks to its involvement
in essential processes such as migration, invasiveness and
cytokine signaling. Though laboratory cell experimental
studies are good models to study the genetics of cancer,
however they might not permit to clarify and to under-
stand the epigenetic surrounding the carcinogenesis. Des-
pite this consideration, that aspect is linked to several
clinical trials sustained at present whose emerging data
indicate that RAD001, even well tolerated, has only mod-
erate antitumor efficacy in HCC patients [35, 36].
The mechanisms by which immunosuppressive drugs
can influence neoplasia is complex; and, as suggested by
Bugelski et al, the identification of the relative risk for
patients from preclinical data remains problematic.
On the other hand, classifying immunosuppressive
drugs based on their mechanism of action and hazard
identification from preclinical studies to monitor car-
cinogenic risk may be a feasible way to manage patient
safety [37].
In fact, antineoplastic properties of mTOR-I seem to
be limited and might be enhanced by the contemporary
inhibition of the crosstalk among mTORC1, mTORC2
and Phosphatidylinositol-3 kinase (PI3K)/AKT [8, 38].
Our in vitro study reveals new biological/cellular aspects
of the pro-fibrotic activity of EVE and it demonstrates, for
the first time, that an EMT program in parenchymal and
non-parenchymal liver cells may be activated by high
doses of this drug. Additionally, these data, confirming
previous evidence [39], suggest that clinicians should ad-
minister the adequate dosage of EVE in order to increase
efficacy and reduce adverse effects. Further studies are
needed about PI3K/Akt/mTOR pathway may prevent the
EMT process EVE-dependent and optimized its antitumor
effect.Conclusions
Liver EMT and consequent fibrosis is characterized by an
orchestrated, highly regulated process. Altogether, our data,
although obtained in an in vitro model, reveal new
biological/cellular aspects of the liver and systemic pro-
fibrotic machinery induced by high-dose EVE treatment; if
confirmed by additional studies, they could be useful for
researchers to develop new therapeutic strategies that may
increase efficacy and reduce potential adverse affects of
EVE also in the field of cancer.
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